The trebling of the S&P 500 index in the last ten years has left the US market accounting for 57% of the MSCI All Countries World index. Much of this outperformance is justified by strong domestic growth, international expansion, rising margins, lower taxes and, above all, America’s record of innovation – but, arguably, not all of it. The earnings multiple of the World index, based on forecast earnings for 2021, stands at nearly 20 but that of the S&P 500 is at 22.5, the highest since 2001. The rest of the world averages out at 16.
Value in the wider market
That has prompted many to conclude that the US market is overvalued. Priyesh Parmar of brokers Numis, however, points out that smaller companies have been left behind. Though the small-cap Russell 2000 index has been outperforming since November, it trades on a discount to the S&P of over 20%, the lowest rating for nearly 20 years. By the standards of the last ten years, smaller companies are moderately expensive but not nearly as expensive as larger companies, while interest rates and bond yields are much, much lower than their historic average – a backdrop that would tend to justify high valuations. Given the long term record of small-cap outperformance globally and in the US, this looks like an anomaly and, Parmar believes, the £250m JPMorgan US Smaller Companies Trust (LSE: JUSC) is the best way to take advantage of it. JUSC is managed by Don San Jose, but his style is far removed from that implied by his swashbuckling name. San Jose looks for “quality companies with a sustainable competitive advantage and a high return on capital”. There is a strong valuation discipline, so the portfolio of 81 holdings has a significantly lower valuation than the index, despite higher earnings growth and a higher return on equity.
With 85% of the portfolio in companies with a market value above $2bn, San Jose is invested at the larger end of a small-cap universe of 2,000 companies. No holding is worth more than 2% of the portfolio, the sectoral composition of which differs markedly from the S&P 500 and the Russell 2000.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Exposure to technology at 13% is a little below the index but healthcare, at 12%, is well below. There is no exposure to biotechnology (“no consistency of earnings”) nor to energy. Instead, San Jose is overweight financials and industrials. Annual portfolio turnover of 20% is not high and it has clearly been no impediment to performance.
Since his appointment in 2008, San Jose has outperformed the Russell 2000, returning 17.8% a year against the index’s 14.8%. Over one and five years, performance kept up with the outperforming S&P 500. Should small caps outperform over the next few years, JUSC’s performance can be expected to move well ahead. Performance is also well ahead of the £160m Jupiter US Smaller Companies Trust (LSE: JUS) but the latter’s management has recently been moved to the well-regarded Brown Advisory so competition is likely to stiffen. While JUSC trades on a premium to net asset value and is issuing shares, JUS is still on a 10% discount.
Time to catch up
If the valuation of the S&P 500 is not to get dangerously ahead of earnings, it may need to trade sideways for much of 2021. But in the meantime there is plenty of scope for a small-cap catch-up, particularly given the enormous pent-up demand in the US economy. As Ed Yardeni, of Yardeni Research, shows, forward earnings estimates for mid and small caps are rising at a record pace and are poised to reach all-time highs, yet the tiddlers have seen nothing like the rerating of the S&P 500. JUSC is an ideal way to profit from the opportunity: a well-managed trust at the neglected end of a core market with great prospects. The only question is why is the trust so small? It should be much larger.
-
FTSE 100 dividends: where to find the best yields for UK equitiesFTSE 100 dividend forecasts have plateaued but investors can still find good yields in UK equities with payments expected to reach £78.6bn in 2024
-
Will the R&D tax credit change in the Autumn Budget?Will Labour revise state help designed to foster R&D in the upcoming Autumn Budget?
-
LSL Property Services: a profit-machine in the property sectorLSL covers every area of the residential real estate market and should thrive after its shake-up
-
Global car shares slide amid lower demand in China – what happens now?Has the car sector run into trouble? Britain’s Aston Martin and Germany’s Volkswagen are among the key automobile brands that have issued profit warnings.
-
Qualcomm could acquire rival Intel – but securing the deal won't be easyA tie-up between Qualcomm and its semiconductor rival Intel would be a coup. But multiple regulatory and commercial hurdles lie ahead.
-
How to invest in the quiet market monthsHere's how to invest in the quiet market months, since “sell in May” hasn’t paid off this year.
-
Spire Healthcare: invest in the booming demand for private healthcareSpire Healthcare is one of the few listed companies benefiting from the growing trend in private healthcare. Should you invest?
-
Are insurance companies a good investment?Costs may be soaring but the insurance sector is currently going through one of its most profitable periods. The market has been slow to realise the opportunity here
-
Google's legal challenges – could it be broken up?Google is fending off legal challenges from both the EU and the US. But would breaking it up actually work?
-
Apple shares slide amid underwhelming demand for new iPhoneApple shares fell last week after disappointing demand for the new iPhone 16 Pro. Can Apple depend on AI to give it a boost?
